Proton Pump Inhibitors and Risk for Recurrent Clostridium difficile Infection Among Inpatients

OBJECTIVES:Observational studies suggest that proton pump inhibitors (PPIs) are a risk factor for incident Clostridium difficile infection (CDI). Data also suggest an association between PPIs and recurrent CDI, although large-scale studies focusing solely on hospitalized patients are lacking. We therefore performed a retrospective cohort analysis of inpatients with incident CDI to assess receipt of PPIs as a risk factor for CDI recurrence in this population.METHODS:Using electronic medical records, we identified hospitalized adult patients between 1 December 2009 and 30 June 2012 with incident CDI, defined as a first positive stool test for C. difficile toxin B and who received appropriate treatment. Electronic records were parsed for clinical factors including receipt of PPIs, other acid suppression, non-CDI antibiotics, and comorbidities. The primary exposure was in-hospital PPIs given concurrently with C. difficile treatment. Recurrence was defined as a second positive stool test 15–90 days after the initial positive test. C. difficile recurrence rates in the PPI exposed and unexposed groups were compared with the log-rank test. Multivariable Cox proportional hazards modeling was performed to control for demographics, comorbidities, and other clinical factors.RESULTS:We identified 894 inpatients with incident CDI. The cumulative incidence of CDI recurrence in the cohort was 23%. Receipt of PPIs concurrent with CDI treatment was not associated with C. difficile recurrence (hazard ratio (HR)=0.82; 95% confidence interval (CI)=0.58–1.16). Black race (HR=1.66, 95% CI=1.05–2.63), increased age (HR=1.02, 95% CI=1.01–1.03), and increased comorbidities (HR=1.09, 95% CI=1.04–1.14) were associated with CDI recurrence. In light of a higher 90-day mortality seen among those who received PPIs (log-rank P=0.02), we also analyzed the subset of patients who survived to 90 days of follow-up. Again, there was no association between PPIs and CDI recurrence (HR=0.87; 95% CI=0.60–1.28). Finally, there was no association between recurrent CDI and increased duration or dose of PPIs.CONCLUSIONS:Among hospitalized adults with C. difficile, receipt of PPIs concurrent with C. difficile treatment was not associated with CDI recurrence. Black race, increased age, and increased comorbidities significantly predicted recurrence. Future studies should test interventions to prevent CDI recurrence among high-risk inpatients.

[1]  D. Adler,et al.  Clostridium difficile-Associated Diarrhea and Proton Pump Inhibitor Therapy: A Meta-Analysis , 2012, The American Journal of Gastroenterology.

[2]  C. Reickert,et al.  Clostridium Difficile of the Ileum Following Total Abdominal Colectomy, With or Without Proctectomy: Who Is at Risk? , 2012, Diseases of the colon and rectum.

[3]  C. Kelly,et al.  Clostridium difficile--more difficult than ever. , 2008, The New England journal of medicine.

[4]  Mary K Goldstein,et al.  Accuracy of computerized outpatient diagnoses in a Veterans Affairs general medicine clinic. , 2002, The American journal of managed care.

[5]  W. DuMouchel,et al.  Unlocking Clinical Data from Narrative Reports: A Study of Natural Language Processing , 1995, Annals of Internal Medicine.

[6]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[7]  Susan S. Huang,et al.  Frequent Hospital Readmissions for Clostridium difficile Infection and the Impact on Estimates of Hospital-Associated C. difficile Burden , 2012, Infection Control & Hospital Epidemiology.

[8]  J. Inadomi,et al.  Overutilization of Proton Pump Inhibitors: A Review of Cost-Effectiveness and Risk in PPI , 2009, The American Journal of Gastroenterology.

[9]  George Hripcsak,et al.  A comparison of the Charlson comorbidities derived from medical language processing and administrative data , 2002, AMIA.

[10]  W. Graninger,et al.  Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  J. Bartlett,et al.  Clinical practice. Antibiotic-associated diarrhea. , 2002, New England Journal of Medicine.

[12]  C. Surawicz,et al.  Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  A. Weintraub,et al.  Comparison of a Commercial Multiplex Real-Time PCR to the Cell Cytotoxicity Neutralization Assay for Diagnosis of Clostridium difficile Infections , 2009, Journal of Clinical Microbiology.

[14]  Steven H. Brown,et al.  Automated identification of postoperative complications within an electronic medical record using natural language processing. , 2011, JAMA.

[15]  Ji Won Kim,et al.  Proton pump inhibitors as a risk factor for recurrence of Clostridium-difficile-associated diarrhea. , 2010, World journal of gastroenterology.

[16]  D. Musher,et al.  Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis. , 2007, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[17]  K. Wilson,et al.  Population dynamics of ingested Clostridium difficile in the gastrointestinal tract of the Syrian hamster. , 1985, The Journal of infectious diseases.

[18]  Mark Miller,et al.  Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  D. Yadav,et al.  Clostridium difficile colitis: factors influencing treatment failure and relapse—a prospective evaluation , 1998, American Journal of Gastroenterology.

[20]  M. Howell,et al.  Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. , 2010, Archives of internal medicine.

[21]  A. Gurevich,et al.  Risk Factors for Recurrence of Clostridium Difficile-associated Diarrhea in the Elderly , 2002, Scandinavian journal of infectious diseases.

[22]  K. Garey,et al.  Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. , 2008, The Journal of hospital infection.

[23]  R. Cavallazzi,et al.  Risk of Clostridium difficile Infection With Acid Suppressing Drugs and Antibiotics: Meta-Analysis , 2012, The American Journal of Gastroenterology.

[24]  A. Zinsmeister,et al.  The Epidemiology of Community-Acquired Clostridium difficile Infection: A Population-Based Study , 2012, The American Journal of Gastroenterology.

[25]  V. Debari,et al.  Diabetes mellitus as a risk factor for recurrence of Clostridium difficile infection in the acute care hospital setting. , 2011, American journal of infection control.

[26]  Carol Friedman,et al.  An automated tool for detecting medication overuse based on the electronic health records , 2013, Pharmacoepidemiology and drug safety.

[27]  S. Maroo,et al.  Recurrent clostridium difficile. , 2006, Gastroenterology.

[28]  A. Robicsek,et al.  Detection of toxigenic Clostridium difficile in stool samples by real-time polymerase chain reaction for the diagnosis of C. difficile-associated diarrhea. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  S. Chapman,et al.  Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database , 1998, BMJ.

[30]  Anders F. Andersson,et al.  Short-Term Antibiotic Treatment Has Differing Long-Term Impacts on the Human Throat and Gut Microbiome , 2010, PloS one.

[31]  L. Winston,et al.  Does doxycycline protect against development of Clostridium difficile infection? , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  C. Donskey,et al.  In Vitro Killing of Nosocomial Pathogens by Acid and Acidified Nitrite , 2006, Antimicrobial Agents and Chemotherapy.

[33]  T. Ferris,et al.  Who is Using Chronic Acid Suppression Therapy and Why? , 2003, American Journal of Gastroenterology.

[34]  A. Barkun,et al.  Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection , 2008, Canadian Medical Association Journal.

[35]  Scot E Dowd,et al.  Effect of the proton pump inhibitor omeprazole on the gastrointestinal bacterial microbiota of healthy dogs. , 2012, FEMS microbiology ecology.

[36]  Mark A. Miller,et al.  Editorial: How Much Do PPIs Contribute to C. difficile Infections? , 2012, The American Journal of Gastroenterology.

[37]  Ashwin N Ananthakrishnan,et al.  Guidelines for Diagnosis, Treatment, and Prevention of Clostridium difficile Infections , 2013, The American Journal of Gastroenterology.

[38]  A. Barkun,et al.  Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. , 2005, JAMA.

[39]  B. Finlay,et al.  Shifting the balance: antibiotic effects on host–microbiota mutualism , 2011, Nature Reviews Microbiology.

[40]  D. Johnson,et al.  Reported side effects and complications of long-term proton pump inhibitor use: dissecting the evidence. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[41]  K. DeVault.  Iatrogenic Gastric Acid Suppression and the Risk of Nosocomial Clostridium difficile Infection , 2010 .

[42]  Carol Friedman,et al.  Deriving comorbidities from medical records using Natural Language Processing , 2013, AMIA.

[43]  O. Dekkers,et al.  Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. , 2012, The Journal of antimicrobial chemotherapy.

[44]  A. Manges,et al.  Comparative metagenomic study of alterations to the intestinal microbiota and risk of nosocomial Clostridum difficile-associated disease. , 2010, The Journal of infectious diseases.

[45]  L. Lanthier,et al.  Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[46]  Amy Linsky,et al.  Proton pump inhibitors and risk for recurrent Clostridium difficile infection. , 2010, Archives of internal medicine.

[47]  David C. Metz,et al.  Safety of proton pump inhibitor exposure. , 2010, Gastroenterology.

[48]  Adam Wright,et al.  Clinician attitudes toward and use of electronic problem lists: a thematic analysis , 2011, BMC Medical Informatics Decis. Mak..